These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 21894514)

  • 21. NAFLD and cardiovascular diseases: a clinical review.
    Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM
    Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people.
    Sung KC; Wild SH; Kwag HJ; Byrne CD
    Diabetes Care; 2012 Nov; 35(11):2359-64. PubMed ID: 22829522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease: from pathogenesis to patient care.
    Perlemuter G; Bigorgne A; Cassard-Doulcier AM; Naveau S
    Nat Clin Pract Endocrinol Metab; 2007 Jun; 3(6):458-69. PubMed ID: 17515890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1. Fatty liver and non-alcoholic steatohepatitis.
    Saito T; Misawa K; Kawata S
    Intern Med; 2007; 46(2):101-3. PubMed ID: 17220609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease.
    Bhat G; Baba CS; Pandey A; Kumari N; Choudhuri G
    Trop Gastroenterol; 2013; 34(1):18-24. PubMed ID: 23923370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the treatments of non-alcoholic fatty liver disease (NAFLD).
    Quercioli A; Montecucco F; Mach F
    Cardiovasc Hematol Disord Drug Targets; 2009 Dec; 9(4):261-70. PubMed ID: 19751186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
    Baranova A; Tran TP; Birerdinc A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-alcoholic fatty liver disease: current concepts and management strategies.
    Day CP
    Clin Med (Lond); 2006; 6(1):19-25. PubMed ID: 16521351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis and management issues for non-alcoholic fatty liver disease.
    Duvnjak M; Lerotić I; Barsić N; Tomasić V; Virović Jukić L; Velagić V
    World J Gastroenterol; 2007 Sep; 13(34):4539-50. PubMed ID: 17729403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study.
    Kempiński R; Łukawska A; Krzyżanowski F; Ślósarz D; Poniewierka E
    Adv Clin Exp Med; 2019 Dec; 28(12):1615-1620. PubMed ID: 31025557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NAFLD, NASH and liver cancer.
    Michelotti GA; Machado MV; Diehl AM
    Nat Rev Gastroenterol Hepatol; 2013 Nov; 10(11):656-65. PubMed ID: 24080776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].
    Kim HS; Cho YK
    Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin.
    Abenavoli L; Milic N; Capasso F
    Endocrine; 2012 Dec; 42(3):754-5. PubMed ID: 22527892
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pediatric non-alcoholic fatty liver disease: recent advances and challenges].
    Poggiogalle E; Olivero G; Anania C; Ferraro F; Pacifico L
    Minerva Pediatr; 2010 Dec; 62(6):569-84. PubMed ID: 21042270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease and insulin resistance.
    Machado M; Cortez-Pinto H
    Eur J Gastroenterol Hepatol; 2005 Aug; 17(8):823-6. PubMed ID: 16003131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alcoholic fatty liver disease and cardiovascular risk.
    Brea A; Puzo J
    Int J Cardiol; 2013 Aug; 167(4):1109-17. PubMed ID: 23141876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.